中间结核负担地区停用全民卡介苗接种的模型效应
该研究用年龄结构传播动态模型模拟台湾地区2018、2035和2050年停用全民卡介苗接种的后果。弱保护情景下2018-2027年增加2.8例通报结核病例、净避免DALY为-4.1;强保护情景下增加82.9例、净避免DALY为-402.7,提示健康影响为负。强保护情景下若通报率降至每10万人5例以下再停用,可能出现总体健康获益。
要点
- 弱保护情景停用BCG:2018-2027年增加2.8例通报结核病例,净避免DALY为-4.1。
- 强保护情景停用BCG:增加82.9例通报病例,净避免DALY为-402.7,健康影响为负。
- 强保护情景下通报率降至每10万人5例以下再停用,可能出现总体健康获益。
核心结论
- 停用BCG在中间负担地区可能是有依据的,取决于疫苗保护质量及是否可重新聚焦其他结核控制活动以早期发现和治疗。
研究设计与样本
- 年龄结构传播动态模型,校准至台湾地区人口学和年龄别结核通报率;采用弱保护和强保护情景,模拟2018、2035和2050年停用全民BCG后10年内的避免DALY和增量成本,并检验监测引导停用(通报率降至给定阈值时触发)的潜在影响。
主要发现
- 弱保护情景下,2018-2027年停用BCG导致增加2.8例(95%不确定性范围:2.3,3.1)通报结核病例,净避免DALY为-4.1(-7.7,0.8)。
- 强保护情景下,2018-2027年停用BCG导致增加82.9例(72.6,91.6)通报结核病例,净避免DALY为-402.7(-506.6,-301.2),提示健康影响稳健为负。
- 强保护情景下,若结核通报率降至每10万人5例以下时停用BCG,可能出现总体健康获益。
- 对净健康影响最具影响力的疫苗特征是疫苗针对进展为肺结核的保护效力。
- 无论BCG保护水平如何,消除的疫苗接种规划成本大幅超过结核治疗的增量成本。
关键数值与推荐
- 弱保护情景:2018-2027年停用BCG,增加2.8例(95%不确定性范围:2.3,3.1)通报结核病例,净避免DALY为-4.1(-7.7,0.8)。
- 强保护情景:2018-2027年停用BCG,增加82.9例(72.6,91.6)通报结核病例,净避免DALY为-402.7(-506.6,-301.2)。
- 强保护情景下,停用BCG的阈值为结核通报率降至每10万人5例以下。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bacillus Calmette-Guérin (BCG) vaccination is a widely-used public health intervention for tuberculosis (TB) control. In Taiwan, like other intermediate TB burden settings, steadily declining TB incidence raises important questions on whether universal BCG vaccination should be discontinued. Recent surveys on adverse events following immunisation, such as BCG-induced osteomyelitis/osteitis, also suggest a need to re-evaluate the vaccination programme. METHODS: We developed an age-structured transmission dynamic model, calibrated to population demography and age-specific TB notification rates in Taiwan. We adopted 'weak-protection' and 'strong-protection' scenarios, representing a range of characteristics including the duration of BCG protection and vaccine efficacies against TB infection and progression. We estimated averted disability-adjusted life years (DALYs) and incremental costs over 10 years after discontinuing universal BCG vaccination in 2018, 2035, and 2050. We also examined the potential impact of 'surveillance-guided' discontinuation, triggered once notification rates fall to a given threshold. RESULTS: In the weak-protection scenario, discontinuing BCG would result in 2.8 (95% uncertainty range: 2.3, 3.1) additional notified TB cases and -4.1 (-7.7, 0.8) net averted DALYs over 2018-2027. In the strong-protection scenario, 82.9 (72.6, 91.6) additional cases and -402.7 (-506.6, -301.2) averted DALYs would be reported, suggesting a robustly negative health impact. However, in this vaccine scenario, there could be an overall health benefit if BCG is discontinued once TB notification falls below 5 per 100,000 population. The most influential vaccine characteristic for the net health impact is the vaccine efficacy against progression to pulmonary TB. In financial terms, the eliminated cost of the vaccination programme substantially outweighed the incremental cost for TB treatment regardless of BCG protection. CONCLUSIONS: BCG discontinuation may be warranted in intermediate burden settings, depending on the quality of vaccine protection, and the potential for refocusing on other TB control activities for earlier detection and treatment.
引用
- Fu H, Lin HH, Hallett TB, et al. Modelling the effect of discontinuing universal Bacillus Calmette-Guérin vaccination in an intermediate tuberculosis burden setting. Vaccine. 2018. PMID: 30143270. doi:10.1016/j.vaccine.2018.08.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。